LBA23 Pembrolizumab (P) combined with chemotherapy (C) vs C alone as first-line (1L) therapy for advanced urothelial carcinoma (UC): KEYNOTE-361
Ajjai Alva, Tibor Csőszi, Mustafa Özgüroğlu, Nobuaki Matsubara, Lajos Géczi, Sierra Cheng, Yves Fradet, Stéphane Oudard, Christof Vulsteke, Rafael Morales‐Barrera, Aude Fléchon, Şeyda Gündüz, Yohann Loriot, Alejo Rodríguez‐Vida, Ronac Mamtani, Evan Y. Yu, K. Nam, Kazuo Imai, Blanca Homet Moreno, Thomas Powles
Topics & Concepts
MedicineCarboplatinGemcitabineInternal medicineRandomizationCisplatinPembrolizumabPopulationInterim analysisOncologyClinical endpointUrologyMetastatic Urothelial CarcinomaChemotherapyGastroenterologyRandomized controlled trialUrothelial carcinomaCancerImmunotherapyEnvironmental healthBladder cancerBladder and Urothelial Cancer TreatmentsCancer Immunotherapy and BiomarkersUrinary and Genital Oncology Studies